Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: Predicted breakpoints versus clinically achievable values for seven fluoroquinolones

被引:15
作者
Firsov, AA
Lubenko, IY
Vostrov, SN
Portnoy, YA
Zinner, SH
机构
[1] Russian Acad Med Sci, Dept Pharmacokinet & Pharmacodynam, Gause Inst New Antibiot, Moscow 119021, Russia
[2] Russian Acad Med Sci, Inst Normal Physiol, Moscow 119021, Russia
[3] Harvard Univ, Sch Med, Mt Auburn Hosp, Cambridge, MA 02138 USA
关键词
D O I
10.1128/AAC.49.7.2642-2647.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Prediction of the relative efficacies of different fluoroquinolones is often based on the ratios of the clinically achievable area under the concentration-time curve (AUC) to the MIC, usually with incorporation of the MIC,,, or the MIC,, and with the assumption of antibiotic-independent patterns of the AUC/MIC-response relationships. To ascertain whether this assumption is correct, the pharmacodynamics of seven pharmacokinetically different quinolones against two clinical isolates of Staphylococcus aureus were studied by using an in vitro model. Two differentially susceptible clinical isolates of S. aureus were exposed to two 12-h doses of ciprofloxacin (CIP) and one dose of gatifloxacin (GAT), gemilloxacin (GEM), grepafloxacin (GRX), levofloxacin (LVX), moxifloxacin (MXF), and trovafloxacin (TVA) over similar AUC/MIC ranges from 58 to 932 h. A specific bacterial strain-independent AUC/MIC relationship with the antimicrobial effect (I-E) was associated with each quinolone. Based on the I-E-log AUC/MIC relationships, breakpoints (BPS) that are equivalent to a CIP AUC/MIC ratio of 125 It were predicted for GRX, MXF, and TVA (75 to 78 h), GAT and GEM (95 to 103 h) and LVX (115 h). With GRX and LVX, the predicted BPS were close to those established in clinical settings (no clinical data on other quinolones are available in the literature). To determine if the predicted AUC/MIC BPS are achievable at clinical doses, i.e., at the therapeutic AUC(5) (AUC(ther)s), the AUC(ther)/MIC50 ratios were studied. These ratios exceeded the BPs for GAT, GEM, GRX, MXF, TVA, and LVX (750 mg) but not for CIP and LVX (500 mg). AUC/MIC ratios above the BPS can be considered of therapeutic potential for the quinolones. The highest ratios of AUC(ther) MIC50 to BP were achieved with TVA, MXF, and GEM (2.5 to 3.0); intermediate ratios (1.5 to 1.6) were achieved with GAT and GRX; and minimal ratios (0.3 to 1.2) were achieved with CIP and LVX.
引用
收藏
页码:2642 / 2647
页数:6
相关论文
共 50 条
[1]  
ADAM B, 1998, ANTIINFECT DRUG CHEM, V16, P70
[2]   Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers [J].
Allen, A ;
Bygate, E ;
Oliver, S ;
Johnson, M ;
Ward, C ;
Cheon, AJ ;
Choo, YS ;
Kim, IC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1604-1608
[3]   Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [J].
Bauernfeind, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :639-651
[4]  
BERGAN T, 1987, AM J MED, V82, P97
[5]  
BERGAN T, 1986, P 1 INT CIPR WORKSH, V34, P111
[6]   THE IN-VITRO ACTIVITY OF CP-99,219, A NEW NAPHTHYRIDONE ANTIMICROBIAL AGENT - A COMPARISON WITH FLUOROQUINOLONE AGENTS [J].
CHILD, J ;
ANDREWS, J ;
BOSWELL, F ;
BRENWALD, N ;
WISE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (06) :869-876
[7]   CONCENTRATIONS OF OPC-17116, A NEW FLUOROQUINOLONE ANTIBACTERIAL, IN SERUM AND LUNG COMPARTMENTS [J].
COOK, PJ ;
ANDREWS, JM ;
WISE, R ;
HONEYBOURNE, D ;
MOUDGIL, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (02) :317-326
[8]   Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci [J].
Coque, TM ;
Singh, KV ;
Murray, BE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (05) :1011-1016
[9]   Ciprofloxacin - An updated review of its pharmacology, therapeutic efficacy and tolerability [J].
Davis, R ;
Markham, A ;
Balfour, JA .
DRUGS, 1996, 51 (06) :1019-1074
[10]   Pharmacokinetics of grepafloxacin [J].
Efthymiopoulos, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 :35-43